Puma Biotechnology Inc (PBYI) - Total Assets
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) holds total assets worth $216.30 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Puma Biotechnology Inc (PBYI) shareholders funds for net asset value and shareholders' equity analysis.
Puma Biotechnology Inc - Total Assets Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's total assets have evolved over time, based on quarterly financial data.
Puma Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Puma Biotechnology Inc's total assets of $216.30 Million consist of 75.2% current assets and 24.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.7% |
| Accounts Receivable | $53.65 Million | 24.8% |
| Inventory | $5.51 Million | 2.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $41.39 Million | 19.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Puma Biotechnology Inc (PBYI) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Puma Biotechnology Inc's current assets represent 75.2% of total assets in 2025, a decrease from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2025, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 24.8% of total assets.
Puma Biotechnology Inc Competitors by Total Assets
Key competitors of Puma Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Puma Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.54 | 1.17 |
| Quick Ratio | 1.93 | 1.45 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $81.43 Million | $51.55 Million | $23.36 Million |
Puma Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Puma Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.70 |
| Latest Market Cap to Assets Ratio | 1.76 |
| Asset Growth Rate (YoY) | 1.4% |
| Total Assets | $216.30 Million |
| Market Capitalization | $381.06 Million USD |
Valuation Analysis
Above Book Valuation: The market values Puma Biotechnology Inc's assets above their book value (1.76x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Puma Biotechnology Inc's assets grew by 1.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Puma Biotechnology Inc (2007–2025)
The table below shows the annual total assets of Puma Biotechnology Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $216.30 Million | +1.39% |
| 2024-12-31 | $213.33 Million | -7.46% |
| 2023-12-31 | $230.53 Million | +3.81% |
| 2022-12-31 | $222.06 Million | -2.00% |
| 2021-12-31 | $226.59 Million | -7.22% |
| 2020-12-31 | $244.22 Million | +3.97% |
| 2019-12-31 | $234.91 Million | -9.35% |
| 2018-12-31 | $259.12 Million | +56.55% |
| 2017-12-31 | $165.53 Million | -34.52% |
| 2016-12-31 | $252.79 Million | +5.40% |
| 2015-12-31 | $239.84 Million | +47.36% |
| 2014-12-31 | $162.76 Million | +55.94% |
| 2013-12-31 | $104.37 Million | -31.20% |
| 2012-12-31 | $151.70 Million | +173.83% |
| 2011-12-31 | $55.40 Million | +11990845.24% |
| 2010-12-31 | $462.00 | -80.81% |
| 2009-12-31 | $2.41K | +3198.63% |
| 2008-12-31 | $73.00 | -99.99% |
| 2007-12-31 | $1.41 Million | -- |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more